RRx-001, a downregulator of the CD47- SIRPα checkpoint pathway, does not cause anemia or thrombocytopenia

In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit

(2021) Yusuke Tomita et al.   Translational Lung Cancer Research

PPARγ-Independent Side Effects of Thiazolidinediones on Mitochondrial Redox State in Rat Isolated Hearts

(2020) Matthias L. Riess et al.   Cells

Industry shows increased appetite for macrophage biology

(2020) Chris Morrison   NATURE REVIEWS DRUG DISCOVERY

The small-cell lung cancer drug market

(2020) Joshua B. N. Dawkins et al.   NATURE REVIEWS DRUG DISCOVERY

RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages

(2019) Pedro Cabrales   Translational Oncology

Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors

(2019) Thomas W. Miller et al.   PLoS One

REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer

(2019) Bryan Oronsky et al.   Future Oncology

IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47–SIRPα Checkpoint Inhibition

(2019) Louise W. Treffers et al.   Cancer Immunology Research

Therapeutic Inhibition of Myc in Cancer. Structural Bases and Computer-Aided Drug Discovery Approaches

(2018) Lavinia Carabet et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

RRx-001 protects against cisplatin-induced toxicities

(2017) Bryan Oronsky et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials

(2016) Bryan Oronsky et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases

(2016) Michelle M. Kim et al.   NEURO-ONCOLOGY

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial

(2016) Michelle M. Kim et al.   Translational Oncology

RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors

(2016) Bryan Oronsky et al.   Clinical Epigenetics

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study

(2015) Tony Reid et al.   LANCET ONCOLOGY

NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001

(2015) Jan Scicinski et al.   Redox Biology

Thrombospondin-1 Signaling through CD47 Inhibits Self-renewal by Regulating c-Myc and Other Stem Cell Transcription Factors

(2013) Sukhbir Kaur et al.   Scientific Reports